Clinical Trials Browser

NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Phase 2 Not yet recruiting

160 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07561983 2026-05-01

BEACON-Lung

Phase 2 Not yet recruiting

39 enrolled

Thoracic

Unresectable Stage III Non-small Cell Lung Cancer

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Phase 3 Not yet recruiting

562 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07485920 2026-03-20

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

Phase 4 Not yet recruiting

20 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07432984 2026-02-25

FMT-LUNG

Phase 2 Not yet recruiting

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

500 enrolled

Thoracic

Non Squamous Non-small Cell Lung Cancer

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Phase 2 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4 Not yet recruiting

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06883552 2025-03-19

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06793228 2025-01-27

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Phase 2 Not yet recruiting

250 enrolled

Thoracic

SCLC, Extensive Stage

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

430 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06607926 2024-09-23

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Phase NA Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

178 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Phase 2 Not yet recruiting

29 enrolled

Thoracic

NSCLC

NCT06375109 2024-04-19

NeoSCLC-001

Phase 2 Not yet recruiting

60 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

642 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung